Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Simple Assessment

Simple Assessment

posted on Aug 02, 2007 01:56PM

I look at this investment in somewhat simple terms with a sucess rating of 8

on scale of 10.  Think about it, the annual licensee fee's should approach $40 M with the ccurrent 20 licensee's with yet hopefully more to be announced.Then, there must be a substantial tax loss carry forward, so PTSC essentially keeps all the earnings for acquistions and/or internal investment needs.  Now according to JT the stock option issue with S/L is resolved.  Now hopefully PTSC will not pay dividends (since obviously it did nothing for the PSP, but I expect it did satisfy an internal greed at sarcify to retail buyer)amounting to approximately $15 M that could have been better spent buying back shares, and/or as retained cash (cash is king) to be used  more fiduciarily.  It appears the patent infringements will certainly resolve in PTSC/TPL favor (of course one never knows in our court system) and this surely is a issue to be concerned with and a stumbling block to overcome in time .  Here I believe the glass is half-full for us.  Now then, with earnings at .10/share ($40M divided by 390M shares) and current price .50, or PE of 5 its obvious in MHO the stock is under valued thanks to MM manupalation. Please comment I have thick skin.

 

Share
New Message
Please login to post a reply